GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » Cyclically Adjusted Book per Share

NeuBase Therapeutics (NeuBase Therapeutics) Cyclically Adjusted Book per Share : $209.78 (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

NeuBase Therapeutics's adjusted book value per share for the three months ended in Sep. 2023 was $2.450. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $209.78 for the trailing ten years ended in Sep. 2023.

During the past 12 months, NeuBase Therapeutics's average Cyclically Adjusted Book Growth Rate was -0.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 6.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of NeuBase Therapeutics was 9.60% per year. The lowest was -12.30% per year. And the median was 6.05% per year.

As of today (2024-06-09), NeuBase Therapeutics's current stock price is $0.378. NeuBase Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $209.78. NeuBase Therapeutics's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of NeuBase Therapeutics was 0.01. The lowest was 0.00. And the median was 0.00.


NeuBase Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for NeuBase Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Cyclically Adjusted Book per Share Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 145.30 158.06 164.62 170.85 191.72

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 211.45 211.27 213.29 211.37 209.78

Competitive Comparison of NeuBase Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, NeuBase Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuBase Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's Cyclically Adjusted PB Ratio falls into.



NeuBase Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NeuBase Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book= Book Value per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=2.45/129.8595*129.8595
=2.450

Current CPI (Sep. 2023) = 129.8595.

NeuBase Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201312 86.919 98.326 114.794
201403 61.046 99.695 79.517
201406 463.111 100.560 598.048
201409 423.693 100.428 547.862
201412 357.916 99.070 469.152
201503 642.937 99.621 838.090
201506 601.174 100.684 775.379
201509 560.346 100.392 724.825
201512 502.313 99.792 653.658
201603 451.803 100.470 583.962
201606 368.461 101.688 470.538
201609 311.298 101.861 396.864
201612 287.442 101.863 366.445
201703 207.164 102.862 261.536
201706 199.061 103.349 250.123
201709 162.609 104.136 202.777
201712 139.553 104.011 174.234
201803 125.062 105.290 154.246
201806 121.718 106.317 148.671
201809 -0.297 106.507 -0.362
201812 71.236 105.998 87.272
201903 63.672 107.251 77.094
201906 56.136 108.070 67.455
201909 11.745 108.329 14.079
201912 8.231 108.420 9.859
202003 4.671 108.902 5.570
202006 30.003 108.767 35.821
202009 27.032 109.815 31.966
202012 24.607 109.897 29.077
202103 20.654 111.754 24.000
202106 36.847 114.631 41.742
202109 33.049 115.734 37.083
202112 28.768 117.630 31.759
202203 23.661 121.301 25.330
202206 18.793 125.017 19.521
202209 14.052 125.227 14.572
202212 10.993 125.222 11.400
202303 8.546 127.348 8.715
202306 5.988 128.729 6.041
202309 2.450 129.860 2.450

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


NeuBase Therapeutics  (NAS:NBSE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NeuBase Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.378/209.78
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of NeuBase Therapeutics was 0.01. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


NeuBase Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Executives
Symetryx Corp 10 percent owner 2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann officer: COO 700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning officer: Chief Financial Officer C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei officer: See Remarks 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall director 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles director 2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast director
Dietrich A Stephan director, 10 percent owner, officer: President and CEO 213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801